In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
Cell-free production method scales up yield by 5,000 times
Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS’s close genetic cousin, the novel coronavirus (COVID-19).
Led by Northwestern University and ShanghaiTech University, the team has produced the promising molecule, called valinomycin, in a cell-free system. With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.
“Because we use cell-free systems, we can optimize production faster than in cells to further increase yields,” said Northwestern’s Michael Jewett, who co-led the study. “For example, pathway optimization cycles take days rather than weeks or months, and this speed could be ever so important when dealing with a pandemic like the coronavirus COVID-19 outbreak.”
The research was published online recently in the journal Metabolic Engineering and will appear in the July 2020 print issue.
Jewett is the Walter P. Murphy Professor of Chemical and Biological Engineering in the McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. He co-led the work with Jian Li, an assistant professor in the School of Physical Science and Technology at ShanghaiTech.
Jewett leads multiple projects that use cell-free biotechnology to accelerate COVID-19 therapeutics. His group takes the molecular machinery out of cells, and then uses that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner. The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.
5,000x
Cell-free method increases yield by 5,000-fold
A naturally occurring peptide, valinomycin has recently emerged as a potential antiviral to treat SARS. Jewett imagines using cell-free synthetic biology to find similar molecules or to modify valinomycin to make it safer and more potent.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 drug development
- San Diego biotech news: Local maker of mRNA used in COVID-19 vaccine opens new facility
The local manufacturing facility will support the growing momentum behind mRNA-based medicines and vaccines beyond COVID-19.
- AstraZeneca to withdraw Covid-19 vaccine
The Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
- AstraZeneca withdraws COVID-19 vaccine globally months after admitting to side effects in court documents
AstraZeneca said on Tuesday (May 7) it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic. The comp ...
- AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed
The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.
- Risky side effect leads to 'withdrawal' of AstraZeneca COVID-19 vaccine
Months after UK-based pharmaceutical manufacturer AstraZeneca admitted rare and dangerous side effect of its COVID-19 vaccine, the company has announced the withdrawal of the ...
Go deeper with Google Headlines on:
COVID-19 drug development
[google_news title=”” keyword=”COVID-19 drug development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Valinomycin
- Journal of biotechnology
Revelation and cloning of valinomycin synthetase genes in Streptomyces lavendulae ACR-DA1 and their expression analysis under different fermentation and elicitation conditions. Genomic and ...
- Startseite Lexika Lexikon der Chemie Aktuelle Seite:
Valinomycin, cyclo-(-D-Val-Lac-Val-D-Hyv-) 3, ein ringförmiges Depsipeptid mit ionenselektiver antibiotischer Wirkung. Das nach seinem hohen Valingehalt bezeichnete V. enthält als nichtproteinogene ...
- Startseite Lexika Lexikon der Chemie Aktuelle Seite:
I. bilden Poren bzw. einen hydrophilen Kanal durch die Membran (z. B. Gramicidin) oder wirken als mobile Carrier (z. B. Valinomycin). Die Selektivität des I. für bestimmte Ionen ist sehr hoch.
Go deeper with Google Headlines on:
Valinomycin
[google_news title=”” keyword=”valinomycin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]